Biovie is trading 5.21% down at $1.98 in pre-market, with the catalyst unclear.
- It closed at $2.09 on August 25, 2026.
- Searches found no verified company-specific announcement dated August 25 or August 26 explaining the decline; the latest major update remains the August 6 Parkinson’s trial results.
- Broader markets are mixed, with technology-stock futures modestly lower, but moves are too limited to establish a clear macro explanation.